SDGR

Schrödinger, Inc.

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger\'s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Schrödinger, Inc. (SDGR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C (2.3) B- (2.9) A+ (4.6) C+ (2.6) B- (3.1)
2026-11-07 B- (3.0) C (2.3) B- (2.9) A (4.5) C+ (2.7) B- (3.1)
2026-10-31 B- (3.0) C- (2.1) B- (2.9) A+ (4.6) C+ (2.7) B- (3.0)
2026-10-24 B- (3.0) C- (2.1) B- (2.9) A+ (4.5) C+ (2.6) B- (3.0)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe